GMP IPO Watch
Avience Biomedicals IPO 2026: Healthcare and Biopharma Company Targets Expansion in India's Growing Medical Sector
Avience Biomedicals IPO is attracting investor attention as the company strengthens its pr...
Read Article
A
SME IPO
LISTED
BSE, NSE
AVIENCE BOIMEDICALS
Avience Biomedicals IPO
Avience Biomedicals IPO details, live grey market premium (GMP), dates, price band, lot size, subscription & review.
Live GMP Today
₹187.2
+90.0%
Est. Listing: ₹395.20
Price Band
₹196 - ₹208
Per equity share
Lot Size
600 Shares
Min Invest: ₹2,49,600
Issue Size
₹208 Cr
Total Public Offering
Issue Dates
17 June 2026 – 21 June 2026
Bidding period
Subscription
43.79x
Total overall demand
Avience Biomedicals IPO Details
Key facts at a glance| IPO Open Date | 17 June 2026 | IPO Close Date | 21 June 2026 |
|---|---|---|---|
| Basis of Allotment | 22 June 2026 | Listing Date | 24 June 2026 |
| Price Band | ₹196 - ₹208 per share | Face Value | ₹10 per share |
| Market Lot Size | 600 Shares | Min Investment (Retail) | ₹2,49,600 |
| Total Issue Size | ₹208 Cr | Issue Type | Book Built Issue IPO |
| Fresh Issue | — | Offer for Sale (OFS) | — |
| Listing At | BSE, NSE | Issue Category | SME Issue |
| Registrar | TBA | ||
Avience Biomedicals IPO Timetable (Tentative Dates)
| Event | Tentative Date | Status |
|---|---|---|
| IPO Open Date | 17 June 2026 | Confirmed |
| IPO Close Date | 21 June 2026 | Confirmed |
| Basis of Allotment | 22 June 2026 | Tentative |
| Initiation of Refunds | TBA | Tentative |
| Credit of Shares to Demat | TBA | Tentative |
| IPO Listing Date | 24 June 2026 | Tentative |
| Cut-off time for UPI Mandate Confirmation | 5:00 PM on Closing Day | Deadline |
* Note: Timelines are tentative and subject to regulatory confirmation. UPI mandate approvals must be completed by 5:00 PM on the IPO closing day.
Avience Biomedicals IPO Lot Size & Investment Details
Application limits for Retail and HNI investors| Application Category | Lots | Shares | Amount (at Cut-off) |
|---|---|---|---|
| Retail (Min) | 2 Lots | 1,200 Shares | ₹2,49,600 |
| Retail (Max) | 2 Lots | 1,200 Shares | ₹2,49,600 |
| S-HNI (Min) | 3 Lots | 1,800 Shares | ₹3,74,400 |
| S-HNI (Max) | 8 Lots | 4,800 Shares | ₹9,98,400 |
| B-HNI (Min) | 9 Lots | 5,400 Shares | ₹11,23,200 |
Avience Biomedicals IPO Live GMP & Movement History
Daily unofficial grey market trends
Current Grey Market Premium
₹187.2 +90.0%
Estimated Listing Price
₹395.20
| Date | IPO GMP (₹) | Estimated Listing Price | Estimated Listing Gain (%) |
|---|---|---|---|
| 23 Jun 2026 | ₹70 | ₹278.00 | +33.65% |
| 22 Jun 2026 | ₹70 | ₹278.00 | +33.65% |
| 19 Jun 2026 | ₹85 | ₹293.00 | +40.87% |
| 18 Jun 2026 | ₹75 | ₹283.00 | +36.06% |
Disclaimer: Grey Market Premium (GMP) figures are purely unofficial and indicative rates traded in the unregulated grey market. GMP is highly volatile and does not guarantee the actual listing price. Always consult a SEBI registered investment advisor before bidding.
Avience Biomedicals IPO Subscription Status
Demand breakdown by investor category
Retail
58.97x
QIB
0.03x
NII / HNI
—
Total
43.79x
About Avience Biomedicals
Avience Biomedicals IPO Reservation & Share Quotas
The Avience Biomedicals IPO allocation structure is divided among different investor categories such as QIB, NII, and retail investors. This structured distribution ensures balanced participation from institutional and individual investors during the subscription phase.
A significant portion of shares is allocated to retail investors, encouraging broader public participation, while institutional segments help provide stability and demand visibility for the issue.
| Investor Category | Shares Offered | Shares (%) |
|---|---|---|
| Anchor Investor | 4,09,800 Shares | 28.19% |
| QIB (Ex. Anchor) | 2,73,600 Shares | 18.82% |
| NII Shares Offered | 2,07,000 Shares | 14.24% |
| Retail Shares Offered | 4,81,200 Shares | 33.10% |
Avience Biomedicals IPO Anchor Investors
The anchor investor segment of Avience Biomedicals IPO plays a key role in building early confidence for the issue. These investors participate before the public subscription window opens, helping establish initial demand visibility and pricing stability.
Lock-in requirements ensure that a portion of the anchor allocation remains invested for a defined period after listing, supporting market stability in the early trading phase.
| Particular | Details |
|---|---|
| Anchor Bidding Date | June 17, 2026 |
| Anchor Investors List | |
| Shares Offered | [.] Shares |
| Anchor Size | [.] Cr. |
| Lock-in (50% shares - 30 Days) | 2026 |
| Lock-in (50% shares - 90 Days) | 2026 |
Avience Biomedicals IPO Important Dates
| Particular | Dates |
|---|---|
| IPO Open Date | 18 Jun 2026 |
| IPO Close Date | 22 Jun 2026 |
| Basis of Allotment | 23 Jun 2026 |
| Refunds | - |
| Credit to Demat Account | - |
| IPO Listing Date | 25 Jun 2026 |
Note: The timeline for Avience Biomedicals IPO is tentative and subject to change.
Avience Biomedicals Promoters and Shareholding Pattern
The promoter group of Avience Biomedicals consists of experienced individuals who are actively involved in managing the company’s operations and strategic growth. Their continued presence ensures stability in leadership even after the public issue.
Although the IPO introduces public shareholders, the promoters will retain a significant stake in the company post listing, ensuring strong control and long-term commitment to business expansion.
| Particular | Shares | % Share |
|---|---|---|
| Promoter Holding Pre Issue | 40,31,256 | 87.89% |
| Promoter Holding Post Issue | 54,85,056 | 64.59% |
Avience Biomedicals Objects of the Issue & Utilisation of Proceeds
To Be Updated Soon
Avience Biomedicals About the IPO
Avience Biomedicals Limited, founded in June 2024, is a prominent manufacturer, supplier, and exporter of molecular diagnostic products, testing solutions, and laboratory equipment. The firm specializes in molecular biotechnology, genomics, and in vitro diagnostics (IVD). Avience Biomedicals Limited enhanced its product range from IVD rapid test kits to an extensive line of medical devices, including biochemistry, hematology, and serology products.
Its product range includes Rapid Test Kits, Biochemistry Analyzers and Reagents, Molecular Diagnostics, Hematology Analyzers, and Medical Devices. The company’s products are distributed to Pathology Labs, Microbiology Labs, Hospitals, and Research Centers nationwide and overseas as well. Along with manufacturing, the firm also serves as a distributor and trader of medical equipment. Moreover, its manufacturing facility is located in Noida, Uttar Pradesh.
Avience Biomedicals Company Financial Report
To Be Updated Soon
Avience Biomedicals Company Valuation & Key Performance Indicators
To Be Updated Soon
Avience Biomedicals Peer Group Comparison
To Be Updated Soon
Avience Biomedicals Lead Managers & Merchant Bankers
- Fintellectual Corporate Advisors Pvt. Ltd.
Avience Biomedicals IPO FAQs
Avience Biomedicals IPO opens for subscription on 17 June 2026 and closes on 21 June 2026.
The price band for Avience Biomedicals IPO is set at ₹196.00 to ₹208.00 per share.
The minimum market lot size is 600 shares. A retail investor can apply for a minimum of 1 lot requiring an investment of 1,200 Shares (₹2,49,600).
The latest Grey Market Premium (GMP) for Avience Biomedicals IPO is ₹187.20. GMP represents the unofficial premium at which shares trade prior to listing.
The basis of allotment for Avience Biomedicals IPO is tentatively scheduled for 22 June 2026, and shares are expected to list on the stock exchanges on 24 June 2026.
The registrar details will be confirmed in the official prospectus.
Avience Biomedicals IPO Analysis & Articles
